Personalized Dendritic Cell Vaccines

  • Anti-cancer vaccines made of ex vivo-cultured Dendritic cells (DCs) have been found to induce protective and therapeutic anti-tumor immunity.
  • Human tumors express a number of protein antigens that can be recognized by T-cells, thus providing potential targets for cancer immunotherapy.
  • DCs are rare leukocytes that are uniquely potent in their ability to present antigens to T-cells, and this property has prompted their application to therapeutic cancer vaccines.
  • Isolated DCs are loaded with tumor antigen ex vivo using patient-customized vectors or protein co-cultivation.
  • DC vaccines loaded with patient-derived tumor antigens are the safe immunotherapy and they can induce antitumor immunity, even in patients with advanced disease.